On one hand, frequent promoter methylation of COL1A1 was detected in renal cell carcinoma and hepatocellular carcinoma [9, 10], and COL1A2 was downregulated in melanoma [11], head and neck cancer [14], and bladder cancer [15]. This evidence concerns the gene COL1A2 and head and neck cancer.